Mereo is a UK-based specialty biopharma company established to address the R&D and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo’s business model brings clear benefits to these companies, to investors, and to patients.

Big companies’ pipelines are full of promising new drugs, but P&L pressures and competition for R&D resources mean it is difficult for all these pipeline drug candidates to be advanced. Mereo was established to overcome these hurdles, optimise drug development and ensure that promising drug candidates fulfil their potential.

We first identify novel pipeline products in the therapeutic areas of speciality pharma or orphan and rare diseases that have the potential to address significant unmet medical needs. Through an acquisition or licensing structure we then provide the financial and clinical support needed to accelerate progression of these products to the marketplace, creating value for all the respective stakeholders.

Mereo was founded in March 2015. Concurrent with a private financing round of £76.5m in July 2015 with two leading investors Woodford and Invesco, the company acquired an initial portfolio of three strong pipeline products from Novartis, each with a comprehensive and robust package of Phase 2 clinically-meaningful data. In June 2016 the company raised additional capital and joined the London Stock Exchange’s AIM market.

Our Leadership

Our team is highly experienced in clinical development, identifying new product opportunities, capital raising and structuring transactions.

VIew Our Team

Our Strategy

Our goal is to leverage Mereo’s innovative business model and resources to develop novel medicines for patients and to become a leader in specialty biopharma.

View Our Strategy

Our Business Model

We focus on acquiring and delivering Phase 2 drugs to patients, whilst optimising the value of our product portfolio through flexible deal structures.

View our business model